来自官方财务报表的收入、利润与现金流历史。
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
| 利润表 | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| 总收入 | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — |
| 毛利 | — | — | ($16M) | ($75M) | ($9M) | ($2M) | ($1M) | ($1M) | ($1M) | — |
| 毛利率% | — | — | — | — | — | — | — | — | — | — |
| 营业利润（EBIT） | ($1.2B) | ($924M) | ($570M) | ($468M) | ($232M) | ($104M) | ($90M) | ($54M) | ($36M) | ($18M) |
| 营业利润率% | — | — | — | — | — | — | — | — | — | — |
| 净利 | ($1.1B) | ($767M) | ($464M) | ($402M) | ($223M) | ($100M) | ($89M) | ($50M) | ($29M) | ($17M) |
| 净利润率 % | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($1.1B) | ($742M) | ($448M) | ($392M) | ($214M) | ($97M) | ($88M) | ($49M) | ($28M) | ($17M) |
| 每股收益（EPS） | $-7.64 | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 | $-1.03 | $-1.15 | $-4.83 |
| 已发行股数 (M) | 144M | 136M | 122M | 97M | 65M | 52M | 30M | 49M | — | 4M |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 PCVX 交互式查看器。 /companies/us/PCVX
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms